论文部分内容阅读
目的:研究潜阳育阴颗粒对高血压肾病的治疗作用与机制。方法:随机将32只12周龄雄性SHR大鼠等分为4组:模型组(SHR)、潜阳育阴组(SHR+Q)、贝那普利组(SHR+B)、及潜阳育阴+贝那普利组(SHR+Q+B)。另取8只年龄、性别配对的WKY大鼠为正常组。SHR+Q、SHR+B及SHR+Q+B组分别以潜阳育阴混悬液5 g/(kg·d)、贝那普利混悬液1.67 mg/(kg·d)及潜阳育阴混悬液5 g/(kg·d)+贝那普利混悬液1.67mg/(kg·d)灌胃。正常组及模型组不给药,予等量蒸馏水灌胃,五组均正常饮食。灌胃周期共8周。实验前及实验后均采用无创伤性尾静脉测压法测量大鼠血压。实验8周后,用大鼠代谢笼按组分别装大鼠,接取各组大鼠24 h的尿液,采用全自动生化仪和放免法检测大鼠尿m-ALB及尿NAG含量;HE染色观测肾脏病变;Masson染色观察肾组织纤维化;Elisa法检测肾组织Pro、Ald、Ang II含量;Western Blot法检测肾组织ACE、AT1R、CTGF蛋白表达。结果:SHR组血压显著增加,尿液中m-ALB、NAG浓度增高,潜阳育阴颗粒可以降低血压与m-ALB、NAG。模型组出现Ang II、AT1R、CTGF活性的上调,而潜阳育阴颗粒对其有抑制作用。结论:潜阳育阴药物对高血压肾病有治疗作用,减轻高血压肾病过程中的纤维化,推测其治疗高血压肾脏病可能与其干预CTGF通路有关。
Objective: To study the therapeutic effect and mechanism of Qiangyang Yuyin Granule on hypertensive nephropathy. Methods: Thirty-two male SHR rats were randomly divided into 4 groups: model group (SHR), SHR + Q group, SHR + B group, Yu Yin + benazepril group (SHR + Q + B). Another 8 age and sex matched WKY rats for the normal group. The rats in SHR + Q, SHR + B and SHR + Q + B groups were treated with 5 g / (kg · d) of latent Yang Yu Yin suspension, 1.67 mg / (kg · d) of benazepril suspension and Yu Yin suspension 5 g / (kg · d) + benazepril suspension 1.67mg / (kg · d) gavage. The normal group and the model group were not given, the same amount of distilled water gavage, five groups were normal diet. Gavage cycle a total of 8 weeks. Before and after the experiment, noninvasive tail vein manometry was used to measure the blood pressure of rats. Eight weeks after the experiment, rat cages were divided into groups to receive rats for 24 hours. Urinary m-ALB and urinary NAG in rats were detected by automatic biochemical analyzer and radioimmunoassay. HE Kidney lesions were observed by staining; Masson staining was used to observe renal fibrosis; Elisa method was used to detect the contents of Pro, Ald and Ang II in renal tissue; Western blot was used to detect the protein expression of ACE, AT1R and CTGF in renal tissue. Results: The blood pressure in SHR group was significantly increased, while the concentrations of m-ALB and NAG in urine were increased. QianYangYuYin granules could lower blood pressure and m-ALB, NAG. In model group, the up-regulation of Ang II, AT1R and CTGF activity was observed, while Qiangyang Yuyin granule inhibited it. CONCLUSION: The sub-yang-yin-yin drug has a therapeutic effect on hypertensive nephropathy and reduces fibrosis in hypertensive nephropathy. It is speculated that the treatment of hypertension-induced nephropathy may be related to the intervention of CTGF pathway.